oglufanide disodium + paclitaxel + carboplatin

**Oglufanide disodium + paclitaxel + carboplatin** is a triple drug combination and represents a multi-agent chemotherapy regimen. - **Oglufanide disodium** is a synthetic peptide immune modulator believed to stimulate immune responses, though it is not widely approved or established in standard oncology protocols. - **Paclitaxel** is a microtubule-stabilizing agent that promotes the assembly of microtubules and inhibits their disassembly, leading to apoptosis of cancer cells. - **Carboplatin** is a platinum-based agent that crosslinks DNA, thereby inhibiting DNA synthesis and inducing apoptosis in rapidly dividing cells. This combination is investigational. The addition of oglufanide disodium may be intended to enhance immune responses alongside the established cytotoxic effects of paclitaxel and carboplatin, which are used together for treating various solid tumors including lung, ovarian, and breast cancer[6][1][2][3][4][5]. Clinical evidence regarding the triple combination specifically is limited, and both paclitaxel and carboplatin are approved and widely used drugs in oncology. Oglufanide’s use is typically researched as an immunological adjuvant.